Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. increased its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 7.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,039 shares of the company’s stock after purchasing an additional 6,232 shares during the quarter. Dana Investment Advisors Inc. owned 0.16% of Olema Pharmaceuticals worth $537,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vontobel Holding Ltd. acquired a new position in Olema Pharmaceuticals during the 4th quarter worth $62,000. SG Americas Securities LLC boosted its position in shares of Olema Pharmaceuticals by 33.8% during the 4th quarter. SG Americas Securities LLC now owns 17,475 shares of the company’s stock worth $102,000 after acquiring an additional 4,419 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Olema Pharmaceuticals during the 4th quarter worth about $111,000. Conway Capital Management Inc. acquired a new position in shares of Olema Pharmaceuticals during the 3rd quarter worth about $119,000. Finally, Portland Investment Counsel Inc. acquired a new position in shares of Olema Pharmaceuticals during the 3rd quarter worth about $143,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of Olema Pharmaceuticals stock in a transaction dated Wednesday, January 8th. The stock was acquired at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the acquisition, the insider now owns 7,800,000 shares of the company’s stock, valued at approximately $44,928,000. This trade represents a 4.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Cyrus Harmon sold 8,256 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $9.37, for a total value of $77,358.72. Following the completion of the sale, the director now directly owns 772,277 shares of the company’s stock, valued at $7,236,235.49. The trade was a 1.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 773,797 shares of company stock valued at $5,414,609. Insiders own 19.40% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Wednesday, March 5th.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $4.61 on Monday. Olema Pharmaceuticals, Inc. has a 1 year low of $4.07 and a 1 year high of $16.62. The stock has a market cap of $264.14 million, a P/E ratio of -2.11 and a beta of 2.11. The stock has a 50-day simple moving average of $5.35 and a 200-day simple moving average of $8.82.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.